Introducing NOCITA®

(bupivacaine liposome injectable suspension)

Transform the way you control CCL* post-operative pain.

Now you can be sure dogs are getting the post-surgical pain relief they need even after they leave your clinic. New NOCITA® is a long-acting local anesthetic that gives you the control of extended-release delivery of bupivacaine, providing up to 72 hours of post-operative pain relief for cranial cruciate ligament surgery with one dose at closing.

*Cranial cruciate ligament

About NOCITA®

NOCITA® is a long-acting, local anesthetic that lasts up to 72 hours post-surgery by extending the release of bupivacaine over time from multivesicular liposomes deposited in the tissue. The therapeutic is administered as a single dose by tissue infiltration injection during closure of cranial cruciate ligament surgery in dogs.

Controlling post-surgical pain

Post-surgical pain can typically be well controlled in hospitalized patients using a multimodal analgesic regimen involving an appropriate combination of opioids, COX-inhibiting NSAIDs, and long-acting NOCITA®. However, most veterinary patients that undergo surgery are discharged from the veterinary hospital within 24-48 hours. Analgesics must be prescribed and/or delivered that provide continued pain relief in the home environment.

Limitations of local anesthetics (LAs)

One of the most effective means of preventing the transduction and transmission of pain is through the use of LAs. While their post-operative use is supported by AAHA/AAFP and WSAVA Pain Guidelines, there are limitations which function as barriers to their use. These include the technical difficulty associated with some nerve and epidural blocks, potential complications of the indwelling soaker catheter, and the short duration of action (<8 hours) of the available formulations.

Mechanism of Action

The extended-release bupivacaine technology used in NOCITA® consists of multivesicular liposomes composed of hundreds to thousands of chambers per particle. Learn more >

Dosing and Administration

The technique for injecting bupivacaine liposome injectable suspension into a surgical site differs slightly from using traditional bupivacaine formulation. Learn more >

Efficacy

A dog study to measure bupivacaine liposome injectable suspension effectiveness was conducted in 182 client-owned dogs undergoing knee surgery. Learn more >

Safety

Extended-release bupivacaine has been studied in dogs as part of the development for human use. Learn more >

To learn more about how NOCITA® will help raise the standard of care for CCL* post-operative pain management in dogs, watch this video

*Cranial cruciate ligament

Clinical Support

Your convenient one-stop source for viewing, downloading and sharing important information.

Learn more >

News

Keep current on all the latest Aratana news, upcoming conferences and other timely information.

Learn more >

IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.

NOCITA® is now available

ORDER NOW

Other therapeutics from Aratana

ENTYCE logo

ENTYCE® (capromorelin oral solution)
provides appetite stimulation.

Inappetence in dogs is a serious problem. Recently-FDA-approved ENTYCE® provides safe, effective appetite stimulation.

VIEW WEBSITE

IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.